[{"address1": "2 Corporate Drive", "address2": "First Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 239 2030", "website": "https://www.sentibio.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 48, "companyOfficers": [{"maxAge": 1, "name": "Dr. Timothy K. Lu M.D., Ph.D.", "age": 42, "title": "Co-Founder, CEO & Director", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 868569, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kanya  Rajangam M.D., Ph.D.", "age": 49, "title": "President, Head of Research & Development and Chief Medical Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 689991, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James J. Collins Ph.D.", "age": 57, "title": "Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 58500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Wilson  Wong Ph.D.", "title": "Scientific Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yvonne  Li M.B.A.", "age": 63, "title": "Interim CFO, Treasurer & Principal Accounting Officer", "yearBorn": 1960, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas P. Chung", "title": "Vice President of Strategic Finance & Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Dee Olomajeye Dragon", "title": "Vice President of People Strategy & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.2, "open": 2.202, "dayLow": 2.12, "dayHigh": 2.202, "regularMarketPreviousClose": 2.2, "regularMarketOpen": 2.202, "regularMarketDayLow": 2.12, "regularMarketDayHigh": 2.202, "beta": 2.746, "forwardPE": -2.8266666, "volume": 18422, "regularMarketVolume": 18422, "averageVolume": 26145, "averageVolume10days": 23000, "averageDailyVolume10Day": 23000, "bid": 1.59, "ask": 2.75, "bidSize": 200, "askSize": 200, "marketCap": 9707437, "fiftyTwoWeekLow": 1.52, "fiftyTwoWeekHigh": 7.43, "priceToSalesTrailing12Months": 28.720228, "fiftyDayAverage": 2.46606, "twoHundredDayAverage": 3.113845, "currency": "USD", "enterpriseValue": 29501436, "floatShares": 2920793, "sharesOutstanding": 4578980, "sharesShort": 59182, "sharesShortPriorMonth": 69893, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0128999995, "heldPercentInsiders": 0.21004999, "heldPercentInstitutions": 0.23089, "shortRatio": 2.34, "shortPercentOfFloat": 0.0164, "bookValue": 9.655, "priceToBook": 0.21957535, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -78617000, "trailingEps": -17.54, "forwardEps": -0.75, "enterpriseToRevenue": 87.282, "enterpriseToEbitda": -0.521, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SNTI", "underlyingSymbol": "SNTI", "shortName": "Senti Biosciences, Inc.", "longName": "Senti Biosciences, Inc.", "firstTradeDateEpochUtc": 1622035800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "6e1c0497-dfb2-3427-8088-6f54c5e467cc", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.12, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 15947000, "totalCashPerShare": 3.483, "ebitda": -56604000, "totalDebt": 35741000, "quickRatio": 3.817, "currentRatio": 4.89, "totalRevenue": 338000, "debtToEquity": 80.957, "revenuePerShare": 0.075, "returnOnAssets": -0.33019, "returnOnEquity": -1.11069, "freeCashflow": -57737876, "operatingCashflow": -42443000, "operatingMargins": -180.17455, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-11"}]